Area of research
Oncology · Otorhinolaryngology
Research interest
Research interests include Head and Neck Cancer Studies, Lung Cancer Research Studies, Lung Cancer Treatments and Mutations, and Advanced Radiotherapy Techniques.
Nivolumab combined with induction chemotherapy and radiotherapy in nasopharyngeal carcinoma: A multicenter phase 2 PLATINUM trial
Anti-LAG-3 antibody LBL-007 plus anti-PD-1 antibody toripalimab in advanced nasopharyngeal carcinoma and other solid tumors: an open-label, multicenter, phase Ib/II trial
Toripalimab Combination Therapy Without Concurrent Cisplatin for Nasopharyngeal Carcinoma
Abstract CT011: Penpulimab versus placebo in combination with chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A global, multicenter, randomized, double-blind, phase 3 trial (AK105-304)
PBW Basis of the Modified Ringel–Hall Algebra of Type <a:math xmlns:a="http://www.w3.org/1998/Math/MathML" id="M1"> <a:msub> <a:mrow> <a:mi>A</a:mi> </a:mrow> <a:mrow> <a:mi>n</a:mi> </a:mrow> </a:msub> </a:math> via Gröbner–Shirshov Basis
Nimotuzumab plus chemoradiotherapy versus placebo plus chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma (NPC): A prospective, randomized-controlled, double-blinded, multicenter phase III clinical trial.
The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma
Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study)
Chimeric Antigen Receptor T-Cell Therapy in Glioblastoma: Current and Future
PD-L1 predicts poor prognosis for nasopharyngeal carcinoma irrespective of PD-1 and EBV-DNA load
STAT3 inhibitor stattic enhances radiosensitivity in esophageal squamous cell carcinoma